Daniel Skovronsky

17.1k total citations · 4 hit papers
85 papers, 8.2k citations indexed

About

Daniel Skovronsky is a scholar working on Physiology, Psychiatry and Mental health and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel Skovronsky has authored 85 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Physiology, 35 papers in Psychiatry and Mental health and 30 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel Skovronsky's work include Alzheimer's disease research and treatments (52 papers), Dementia and Cognitive Impairment Research (35 papers) and Medical Imaging Techniques and Applications (27 papers). Daniel Skovronsky is often cited by papers focused on Alzheimer's disease research and treatments (52 papers), Dementia and Cognitive Impairment Research (35 papers) and Medical Imaging Techniques and Applications (27 papers). Daniel Skovronsky collaborates with scholars based in United States, Taiwan and Australia. Daniel Skovronsky's co-authors include Virginia M.‐Y. Lee, Mark A. Mintun, Hank F. Kung, Michael J. Pontecorvo, John Q. Trojanowski, Robert W. Doms, Abhinay D. Joshi, Zhi‐Ping Zhuang, Eric M. Reiman and Catherine Hou and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Daniel Skovronsky

85 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Donanemab in Early Alzheimer’s Disease

2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

2014 690 citations Keith A. Johnson, Michael J. Pontecorvo et al. Alzheimer s & Dementia profile →
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

2012 572 citations Christopher M. Clark, Michael J. Pontecorvo et al. profile →
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸F-AV-45 (Flobetapir F 18)

2010 517 citations Dean F. Wong, Paul B. Rosenberg et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Skovronsky United States	40	5.4k	3.2k	1.8k	1.6k	1.1k	85	8.2k
Michael J. Pontecorvo United States	48	4.7k 0.9×	4.3k 1.3×	1.8k 1.0×	1.5k 1.0×	2.5k 2.2×	142	8.9k
Brian J. Lopresti United States	43	3.6k 0.7×	2.8k 0.9×	1.3k 0.7×	1.5k 1.0×	1.6k 1.4×	146	7.8k
Miloš D. Ikonomović United States	50	4.8k 0.9×	2.3k 0.7×	2.5k 1.4×	818 0.5×	1.3k 1.2×	162	9.0k
Michael Schöll Sweden	46	5.2k 1.0×	3.9k 1.2×	1.4k 0.8×	1.2k 0.7×	1.8k 1.6×	164	8.3k
Piotr Lewczuk Germany	49	6.3k 1.2×	4.2k 1.3×	2.8k 1.5×	585 0.4×	1.0k 0.9×	177	10.4k
John M. Ringman United States	42	3.2k 0.6×	1.7k 0.5×	1.6k 0.9×	904 0.6×	1.3k 1.1×	161	7.7k
Eric Siemers United States	45	7.2k 1.3×	4.5k 1.4×	2.6k 1.4×	727 0.5×	1.5k 1.3×	167	12.0k
Holly Soares United States	43	4.8k 0.9×	3.5k 1.1×	3.2k 1.8×	792 0.5×	1.2k 1.1×	97	10.5k
Nigel J. Cairns United States	49	5.1k 1.0×	2.1k 0.6×	3.3k 1.8×	594 0.4×	943 0.8×	118	10.1k
Niels Andreasen Sweden	55	6.4k 1.2×	3.7k 1.1×	3.0k 1.7×	389 0.2×	617 0.5×	120	9.8k

Countries citing papers authored by Daniel Skovronsky

Since Specialization

Citations

This map shows the geographic impact of Daniel Skovronsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Skovronsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Skovronsky more than expected).

Fields of papers citing papers by Daniel Skovronsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Skovronsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Skovronsky. The network helps show where Daniel Skovronsky may publish in the future.

Co-authorship network of co-authors of Daniel Skovronsky

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Skovronsky. A scholar is included among the top collaborators of Daniel Skovronsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Skovronsky. Daniel Skovronsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mintun, Mark A., Craig Ritchie, Paul R. Solomon, et al.. (2024). 1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial. Age and Ageing. 53(Supplement_1). 2 indexed citations

Mintun, Mark A., Craig Ritchie, Paul R. Solomon, et al.. (2023). Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial. Alzheimer s & Dementia. 19(S24). 6 indexed citations

Dougan, Marcelle, Ajay Nirula, Robert Gottlieb, et al.. (2021). Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. 29(1). 33–33. 6 indexed citations

Cohen, Max, Ajay Nirula, Mary Marovich, et al.. (2021). Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. 29(1). 32–33. 4 indexed citations

Mintun, Mark A., Albert Lo, Cynthia Evans, et al.. (2021). Donanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 384(18). 1691–1704. 969 indexed citations breakdown →

Johnson, Keith A., Reisa A. Sperling, Christopher Gidicsin, et al.. (2013). Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer s & Dementia. 9(5S). S72–83. 190 indexed citations

Grundman, Michael, Michael J. Pontecorvo, Stephen Salloway, et al.. (2012). Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. Alzheimer Disease & Associated Disorders. 27(1). 4–15. 93 indexed citations

Joshi, Abhinay D., Michael J. Pontecorvo, Alan Carpenter, et al.. (2012). Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. Journal of Nuclear Medicine. 53(3). 378–384. 301 indexed citations

Fleisher, Adam, Kewei Chen, Xiaofen Liu, et al.. (2012). Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiology of Aging. 34(1). 1–12. 159 indexed citations

10.

Sperling, Reisa A., Keith A. Johnson, P. Murali Doraiswamy, et al.. (2012). Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging. 34(3). 822–831. 105 indexed citations

11.

Normandin, Marc D., Kitt Falk Petersen, Yu‐Shin Ding, et al.. (2012). In Vivo Imaging of Endogenous Pancreatic β-Cell Mass in Healthy and Type 1 Diabetic Subjects Using ¹⁸F-Fluoropropyl-Dihydrotetrabenazine and PET. Journal of Nuclear Medicine. 53(6). 908–916. 89 indexed citations

12.

Lister‐James, John, Michael J. Pontecorvo, Chris M. Clark, et al.. (2011). Florbetapir F-18: A Histopathologically Validated Beta-Amyloid Positron Emission Tomography Imaging Agent. Seminars in Nuclear Medicine. 41(4). 300–304. 59 indexed citations

13.

Zha, Zhihao, Seok Choi, Karl Plöessl, et al.. (2011). Multidentate ¹⁸F-Polypegylated Styrylpyridines As Imaging Agents for Aβ Plaques in Cerebral Amyloid Angiopathy (CAA). Journal of Medicinal Chemistry. 54(23). 8085–8098. 38 indexed citations

14.

Wong, Dean F., Paul B. Rosenberg, Yun Zhou, et al.. (2010). In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine. 51(6). 913–920. 517 indexed citations breakdown →

15.

Skovronsky, Daniel. (2008). Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents.. PubMed. 49(6). 47N–48N. 4 indexed citations

16.

Skovronsky, Daniel & J. Carl Oberholtzer. (2004). Pathologic classification of peripheral nerve tumors. Neurosurgery Clinics of North America. 15(2). 157–166. 79 indexed citations

17.

Kung, Mei‐Ping, Daniel Skovronsky, Catherine Hou, et al.. (2003). Detection of Amyloid Plaques by Radioligands for Aβ40 and Aβ42: Potential Imaging Agents in Alzheimer's Patients. Journal of Molecular Neuroscience. 20(1). 15–24. 34 indexed citations

18.

Skovronsky, Daniel, Virginia M.‐Y. Lee, & Domenico Praticò. (2001). Amyloid Precursor Protein and Amyloid β Peptide in Human Platelets. Journal of Biological Chemistry. 276(20). 17036–17043. 94 indexed citations

19.

Skovronsky, Daniel, Bin Zhang, Mei‐Ping Kung, et al.. (2000). In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Neurobiology of Aging. 21. 178–178. 6 indexed citations

20.

Skovronsky, Daniel & Virginia M.‐Y. Lee. (2000). β-Secretase revealed: starting gate for race to novel therapies for Alzheimer’s disease. Trends in Pharmacological Sciences. 21(5). 161–163. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact